List of Excipients in Branded Drug QTERNMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	QTERNMET	dapagliflozin saxagliptin and metformin hydrochloride	0310-6925	ANHYDROUS LACTOSE	2031-05-12
AstraZeneca Pharmaceuticals LP	QTERNMET	dapagliflozin saxagliptin and metformin hydrochloride	0310-6925	CELLULOSE, MICROCRYSTALLINE	2031-05-12
AstraZeneca Pharmaceuticals LP	QTERNMET	dapagliflozin saxagliptin and metformin hydrochloride	0310-6925	CROSCARMELLOSE SODIUM	2031-05-12
AstraZeneca Pharmaceuticals LP	QTERNMET	dapagliflozin saxagliptin and metformin hydrochloride	0310-6925	CROSPOVIDONE	2031-05-12

QTERNMET Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

QTERNMET XR is a fixed-dose oral combination of saxagliptin and extended-release metformin hydrochloride for adults with type 2 diabetes. Its commercial value is tied to once-daily dosing, controlled metformin release, tablet robustness, and the ability to reproduce the product without compromising saxagliptin stability or metformin dissolution. The strongest opportunities are generic fixed-dose combinations, excipient substitution, regional manufacturing, and differentiated modified-release products. Biosimilar competition is not relevant because QTERNMET XR contains chemically synthesized small molecules rather than a biologic.

What is QTERNMET XR and how is it formulated?

QTERNMET XR combines the DPP-4 inhibitor saxagliptin with extended-release metformin hydrochloride. The product is designed for patients who require both agents and are candidates for once-daily metformin extended-release therapy.[1]

The U.S. product has been supplied in multiple saxagliptin/metformin strengths, including:

Saxagliptin dose	Metformin hydrochloride extended-release dose
2.5 mg	500 mg
2.5 mg	1,000 mg
5 mg	500 mg
5 mg	1,000 mg

The formulation challenge is asymmetric. Saxagliptin is a low-dose active pharmaceutical ingredient, while metformin hydrochloride represents the dominant tablet mass. The excipient system therefore must support:

• Uniform saxagliptin distribution at milligram-level loading.
• High drug loading for metformin hydrochloride.
• Extended release over the intended dosing interval.
• Mechanical strength for a large, potentially difficult-to-swallow tablet.
• Low moisture exposure and adequate chemical stability.
• Consistent dissolution across strengths.
• Robust film coating and tablet identification.

What excipients are used in QTERNMET XR?

The QTERNMET XR prescribing information identifies excipients associated with the tablet core and film coating. The listed inactive ingredients include hypromellose, povidone, magnesium stearate, colloidal silicon dioxide, and coating materials such as hypromellose, titanium dioxide, talc, polyethylene glycol and iron oxide colorants, depending on tablet strength.[1]

Functional role	Likely QTERNMET XR excipient category	Formulation purpose
Extended-release matrix	Hypromellose	Controls water penetration, swelling and metformin diffusion
Binder or granulation aid	Povidone	Improves granule cohesion and content uniformity
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film former	Hypromellose	Provides tablet protection and identification
Opacifier	Titanium dioxide	Improves coating opacity and appearance
Anti-tacking agent	Talc	Supports coating-process performance
Plasticizer or coating aid	Polyethylene glycol	Improves film flexibility
Colorant	Iron oxides	Distinguishes strengths and supports product authentication

The exact excipient grade matters. Hypromellose viscosity, particle size and substitution profile can materially change metformin release. Magnesium stearate concentration and blending time can affect tablet hardness and dissolution. Povidone grade can alter granulation behavior and water uptake.

How does the excipient strategy control metformin extended release?

Metformin hydrochloride is highly water soluble and is present at a high dose. Without a release-controlling matrix, the drug can dissolve rapidly and produce an undesirable release profile. Hypromellose-based hydrophilic matrices address this by forming a hydrated gel layer when exposed to gastrointestinal fluid.

The release mechanism generally involves:

1. Water penetration into the tablet.
2. Hydration and swelling of hypromellose.
3. Formation of a gel barrier.
4. Diffusion and erosion of metformin through the hydrated matrix.
5. Progressive reduction in tablet dimensions during gastrointestinal transit.

The principal development variables are hypromellose viscosity, polymer loading, tablet porosity, compression force and excipient particle-size distribution. A generic manufacturer cannot assume that an equivalent nominal percentage of hypromellose will produce equivalent dissolution. The relevant target is the dissolution profile across the full strength range.

High-dose metformin also creates a tablet-size problem. Increasing polymer concentration can extend release but increase tablet mass. Increasing compression force can improve mechanical strength but reduce porosity and slow hydration. The commercial formulation objective is a tablet that meets dissolution requirements without excessive size or difficult swallowing.

What excipient substitutions create the best commercial opportunities?

The largest opportunity is controlled substitution of noncritical excipients while preserving the product's release and stability profile. Potential targets include:

Hypromellose grade optimization

A manufacturer may evaluate different hypromellose viscosity grades, supplier sources and particle-size distributions. This can reduce cost or improve supply continuity. The change is high impact because the polymer is central to extended-release performance.

Direct compression versus wet granulation

A direct-compression process can reduce processing time, solvent exposure and manufacturing cost. It requires favorable flow, compactibility and content-uniformity performance. Wet granulation may provide better control of low-dose saxagliptin distribution but adds process complexity and residual-moisture risk.

Silicon dioxide and lubricant optimization

Colloidal silicon dioxide can improve flow in a high-dose formulation. Overuse may affect compactibility. Magnesium stearate must be optimized because over-lubrication can weaken tablets and alter dissolution.

Film-coating reformulation

Film coating offers a lower-risk area for cost reduction and supply diversification. Changes in pigment, plasticizer, talc or coating-system supplier are generally more manageable than changes to the release-controlling matrix, provided appearance, identification, moisture protection and dissolution remain acceptable.

Common excipient platform across strengths

A four-strength product line creates an opportunity to use a common manufacturing platform. A shared granulation and coating process can reduce inventory, validation and scale-up costs. The main constraint is maintaining dose proportionality and content uniformity for the low-dose saxagliptin component.

What formulation patents and intellectual property protect QTERNMET XR?

The relevant intellectual-property categories are likely to include:

• Saxagliptin composition-of-matter rights.
• Saxagliptin pharmaceutical composition rights.
• Saxagliptin/metformin combination claims.
• Extended-release metformin formulation claims.
• Tablet architecture and manufacturing-process claims.
• Method-of-use claims for glycemic control.
• Regulatory exclusivity associated with the approved product.

The commercial barrier is not limited to a single patent. A generic applicant must assess the Orange Book entries for the applicable U.S. drug application, including listed patents, expiration dates, pediatric extensions and any patent-term adjustments.[2]

A key distinction is that a formulation patent may cover a particular excipient ratio, release profile or tablet construction, while a method-of-use patent may cover administration in a defined patient population. A Paragraph IV filing can challenge listed patents before their expiration. A non-infringing formulation may still face regulatory and commercial risk if the reference product has enforceable method-of-use or combination claims.

Saxagliptin is a small-molecule product. Patent risk is therefore materially different from biosimilar risk. There is no biologic interchangeability pathway comparable to insulin analogs, monoclonal antibodies or other biological products.

When does QTERNMET lose exclusivity?

QTERNMET XR exclusivity depends on the combination of FDA regulatory exclusivity, listed patents and any applicable patent-term adjustments or extensions. The approval date alone does not establish the generic-entry date.

The FDA approved QTERNMET XR in 2019.[1] For a small-molecule product, the commercial review should separate:

Exclusivity category	Relevance to QTERNMET XR
New chemical entity exclusivity	Generally applies to a new active ingredient, not automatically to a later combination
New clinical investigation exclusivity	May apply if qualifying clinical investigations supported approval
Orphan exclusivity	Not expected for the broad type 2 diabetes indication
Patent protection	May cover saxagliptin, the combination, formulation or use
Pediatric exclusivity	Adds six months when granted to qualifying patents and exclusivities
Regulatory exclusivity for a fixed combination	Depends on the approved application and FDA determination

The practical generic-entry date is the earliest date on which an approved ANDA can launch without violating enforceable patents, subject to litigation, settlement terms and regulatory requirements. A current Orange Book review is required to identify the operative patent estate.[2]

What FDA regulatory pathway applies to generic QTERNMET XR?

A generic version would generally be submitted through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence and bioequivalence to the reference listed drug.[3]

For an extended-release fixed-dose combination, the technical package may require:

• Strength-by-strength comparative dissolution.
• Fed and fasting bioequivalence studies.
• Evaluation of dose dumping risk.
• Saxagliptin and metformin pharmacokinetic measurements.
• Demonstration of content uniformity.
• Control of degradation products and residual solvents.
• Comparative tablet dimensions, where clinically relevant.
• Assessment of alcohol sensitivity if the release system raises that concern.

A formulation that uses different excipients can remain eligible for an ANDA, but the differences must comply with FDA requirements for inactive ingredients and must not alter safety, bioequivalence or performance.[3]

What generic entry risks exist for QTERNMET XR?

The principal generic risks are formulation and regulatory rather than biological.

Low-dose saxagliptin uniformity

Saxagliptin represents a small fraction of total tablet mass. Segregation during blending, transfer or compression can create content-uniformity failures. Ordered mixing, granulation or separate-layer manufacturing may be needed.

Extended-release dissolution

The metformin matrix is the central technical risk. A generic product can meet a single dissolution time point yet fail the overall profile across pH conditions, agitation speeds or strengths.

Large-tablet acceptability

Metformin extended-release tablets are often large because of the high dose. A smaller tablet could offer commercial differentiation, but reducing size can compromise release control and mechanical strength.

Salt and solid-state control

Saxagliptin is commonly handled as a salt form in pharmaceutical development. The selected solid form, water content and particle properties affect blending and stability.

Combination-product complexity

The applicant must demonstrate that the two active ingredients remain stable together and that each strength is bioequivalent. A technically acceptable saxagliptin product is not automatically a QTERNMET XR-equivalent product.

Which commercial opportunities exist for excipient suppliers?

Excipient suppliers can target QTERNMET XR-type products in five areas.

Extended-release polymers

Hypromellose suppliers can compete through controlled viscosity, low batch-to-batch variability, direct-compression grades and technical support for dissolution matching. This is the highest-value excipient category because it directly controls product performance.

Low-moisture processing

Suppliers of low-moisture binders, glidants and lubricants can support improved stability and shorter drying cycles. This is relevant where saxagliptin or the finished combination is sensitive to water activity.

Functional coating systems

Ready-to-use coating systems can reduce development time and improve color consistency across multiple strengths. This opportunity is more accessible than replacing the core release polymer.

Continuous manufacturing excipients

Co-processable excipient systems may improve flow and reduce segregation in a high-dose, low-dose combination. The commercial proposition is strongest where the manufacturer seeks continuous blending or direct compression.

Regional dual sourcing

A second qualified supplier for hypromellose, povidone or coating materials can reduce supply-chain concentration. Regulatory change-control requirements limit rapid substitution, so suppliers with established pharmaceutical grades and global documentation have an advantage.

How does QTERNMET compare with competing diabetes combinations?

QTERNMET XR competes with other oral fixed-dose combinations and with separate-tablet regimens.

Product or regimen	Active ingredients	Main differentiation
QTERNMET XR	Saxagliptin/metformin ER	DPP-4 inhibitor plus once-daily extended-release metformin
Kombiglyze XR	Saxagliptin/metformin ER	Closely related product architecture and therapeutic rationale
Janumet XR	Sitagliptin/metformin ER	Competing DPP-4 inhibitor with metformin
Jentadueto XR	Linagliptin/metformin ER	Competing DPP-4 inhibitor with metformin
Qtern	Dapagliflozin/saxagliptin	DPP-4 inhibitor plus SGLT2 inhibitor, without metformin
Separate tablets	Saxagliptin plus metformin ER	More flexible dosing but lower convenience

The closest product comparison is Kombiglyze XR because it uses the same active ingredients and a similar extended-release metformin concept. QTERNMET XR's commercial differentiation is therefore limited unless it offers meaningful advantages in tablet size, dosing convenience, availability, price or market access.

What is the revenue and licensing opportunity?

The revenue opportunity is more attractive in generic and regional markets than in a premium branded market. The active ingredients are established, and DPP-4 inhibitors face competition from metformin combinations, SGLT2 inhibitors, GLP-1 therapies and low-cost generic alternatives.

Potential commercial models include:

• Contract development and manufacturing of saxagliptin/metformin ER.
• Licensing of a non-infringing extended-release matrix.
• Regional commercialization where the reference product has limited distribution.
• Dual-source excipient supply agreements.
• Smaller-tablet or lower-swallowing-burden reformulations.
• Authorized generic or co-promotion arrangements.
• Export products using country-specific reference products.

The strongest licenseable asset would be a formulation that demonstrates comparable release with lower tablet mass, a simpler manufacturing process or improved stability. An excipient package alone has lower strategic value unless supported by comparative dissolution data, scale-up experience and regulatory documentation.

How strong is the QTERNMET excipient strategy?

The strategy is technically defensible but not highly differentiated. Hypromellose-based metformin extended-release systems are established, and the principal excipients are widely available. The competitive moat is more likely to arise from process control, dissolution matching, regulatory execution and patent position than from the identity of the excipients.

Attribute	Assessment
Excipient availability	High
Formulation complexity	Moderate
Low-dose content-uniformity risk	Moderate to high
Extended-release development risk	Moderate to high
Biosimilar risk	Not applicable
Generic substitution potential	High
Opportunity for smaller-tablet reformulation	Moderate
Patent sensitivity	Potentially high
Premium pricing potential	Limited without clinical or usability differentiation

Key Takeaways

• QTERNMET XR combines saxagliptin with extended-release metformin hydrochloride.
• Hypromellose is the central excipient in the metformin release-control strategy.
• Povidone, colloidal silicon dioxide and magnesium stearate support manufacturability, while hypromellose-based coating systems support protection and identification.
• The main development risks are low-dose saxagliptin uniformity, extended-release dissolution and large-tablet size.
• Generic competition is more relevant than biosimilar competition.
• The best excipient opportunities involve hypromellose grade optimization, direct-compression platforms, coating systems and qualified dual sourcing.
• A current Orange Book and patent-register review is necessary to establish the legally available generic-entry date.
• Commercial differentiation requires more than excipient substitution. Smaller tablets, simpler processing, stronger stability or regional market access are more valuable.

FAQs About QTERNMET Excipient and Commercial Strategy

Is QTERNMET XR an extended-release tablet?

Yes. The product combines saxagliptin with metformin hydrochloride extended release, using a matrix-based approach in which hydrophilic polymer behavior controls metformin release.[1]

Can hypromellose be replaced in a generic QTERNMET XR formulation?

Potentially, but the replacement must reproduce the required release profile, stability and bioequivalence. A different hypromellose grade may be easier to justify than a different polymer system because it preserves the underlying release mechanism.

Does QTERNMET XR have biosimilar competition?

No. Saxagliptin and metformin hydrochloride are small-molecule active ingredients. Competition would proceed through generic-drug pathways rather than biosimilar approval pathways.

What is the most valuable formulation improvement for QTERNMET XR?

A smaller once-daily tablet with equivalent pharmacokinetics and dissolution would likely provide the clearest patient and commercial benefit. The development challenge is retaining metformin release control at high drug loading.

Are formulation excipients alone likely to create a strong patent position?

Usually not. A stronger patent position would require claims directed to a defined composition, release profile, tablet architecture, manufacturing process or clinically relevant performance advantage.

References

1. U.S. Food and Drug Administration. (2019). QTERNMET XR (saxagliptin and metformin hydrochloride extended-release) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2013). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database.